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1 ABBREVATION LIST 
 
CETP    cholesterylester transfer protein 
DMEM  dulbecco's Modified Eagle Medium 
DMSO  dimethyl sulfoxide 
EDTA   ethylene diamine tetraacetic acid 
FBS   foetal bovine serum 
FMLP   N-formyl-methionyl-leucyl-phenylalanine 
GM- CSF  granulocyte- macrophage colony stimulating factor  
GPR109A  G protein coupled receptor 109A 
H2O2   hydrogen peroxide  
HBSS   hank´s balanced salt solution 
IL- 8   interleukin- 8 
k.o.   knock out mice 
LDLR   low-density lipoprotein receptor 
MCP-1  macrophage/monocyte chemotactic protein-1 
MIP-1-α  macrophage inflammatory protein-1-α  
NA   nicotinic acid 
NGS   normal goat serum 
PBS   phosphate buffered saline 
PFA   paraformaldehyde 
PU-REP  pumaG reporter 
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PUMA-G  protein upregulated in macrophages by interferon- gamma 
RANTES regulated upon activation, normal T cell expressed and 
presumably secreted 
RPMI 1640 Roswell park memorial institute tissue medium 1640 
TG 4 %  thioglycolate brewer medium 4 % 
WT   wildtype mice 
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Abstract 
 
 To investigate molecular mechanism of action of nicotinic acid in the treatment 
of atherosclerosis, we have used genetically modified mice, LDLR k.o. mice and 
PumaG double deficient mice. Mice were fed high fat diet for sixteen weeks and treated 
with or without 0.3% nicotinic acid in drinking water. Afterwards mice were sacrificed 
and the hearts were used for determination of the atherosclerotic lesions by defining the 
plaque area and areas immunostained for macrophages.  
 Further we aimed at clearing the mechanism of action of nicotinic acid. By using 
fluorescence microscopy we found area with expression of gene GPR109A in peritoneal 
exudates cells. Next, by setting the limit of intracellular calcium I was measuring the 
response of peritoneal cells to the nicotinic acid with subsequent addition of 
chemokines – mcp-1, rantes, il-8, mip-1- α. The goal was to lower the level of 
chemokines and thus to reduce the inflammation.  
 
 
Abstrakt 
  
 Ke studiu molekulárního mechanismu účinku kyseliny nikotinové v léčbě 
aterosklerózy jsme použili geneticky modifikované myši, LDLR k.o.a PumaG 
deficientní myši. Myši byly krmeny vysokotukovou dietou po dobu šestnácti týdnů a 
zároveň jim byla podávána 0,3% kyselina nikotinová v pitné vodě. Poté byly myši 
usmrceny a srdce použita k určení plochy aterosklerotického plátu a vyjádření 
imunochemicky zbarvených makrofágů.  
 Dále jsme se zaměřili na objasnění mechanismu účinku kyseliny nikotinové. 
Pomocí fluorescenční mikroskopie byla nalezena oblast exprese genu GPR109A 
v buňkách peritoneální zánětlivé tekutiny. Následně pomocí stanovení hladiny 
intracelulárního kalcia byla měřena odpověď peritoneálních buněk na kyselinu nikotinu 
s následným přidáním chemokinů- mcp-1, rantes, il-8, mip-1-α. Záměrem bylo snížení 
hladiny chemokinů a tím snížení zánětu.  
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2  INTRODUCTION 
2.1 Atherosclerosis 
  2.1.1 General patterns about atherosclerosis 
Atherosclerosis is characterized by the thickening of the arterial wall and causes 
coronary artery disease and cerebrovascular disease, the most common causes of illness 
and death worldwide. The efforts to understand how risk factors such as high blood 
pressure, dysregulated blood lipids and diabetes contribute to atherosclerotic disease. 
1
 
Intensive study of the cellular and molecular mechanism that underlies the formation 
of atherosclerotic plaques and plaque rupture has led to a consensus view of these 
processes. 
2
 
At present, the main conceptual approaches to therapy for atherosclerosis are 
manipulation of plasma lipoprotein metabolism or cellular cholesterol metabolism, and 
manipulation of inflammatory processes. 
1
 
Studies of genetically modified mice are commonly used to identify and validate 
potential therapeutic targets. But there is important difference between mice and human 
with respect to process lipoprotein metabolism and to inflammatory pathways. 
3
 
  2.1.2 Initiation and progression of atherosclerosis 
 
 THE NORMAL ARTERY 
Usually a normal artery has three layers (the intima, the media 
and the adventitia). The intima is lined by monolayer of endothelial cells in contact with 
the blood; it contains resident smooth muscle cells incorporated in extracellular matrix. 
The internal elastic lamina forms the border of the intima with the media. The media 
contains layers of smooth muscle cells invested with a collagen- and elastin-rich 
extracellular matrix (the aorta contains concentric lamellae of smooth muscle cells 
which have between dense bands of elastin).  The elastic lamina forms the border 
of the media with the adventitia. The adventitia contains nerves and some mast cells 
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and is the origin of the vessel which supplies blood to the outer two thirds of the tunica 
media.  
ACCUMULATION OF LIPOPROTEIN PARTICLES 
Lipoprotein particles associate with constituents from the extracellular matrix 
and separate from some antioxidants within the intima and in this way can oxidative 
modify. This is a factor that may trigger a local inflammatory response that could be 
responsible for the next steps in the lesions formations.  
ADHESION, PENETRATION AND ACCUMULATION OF LEUKOCYTES 
The luminal endothelial can occur early with adhesion of nuclear leukocytes 
in hypercholesterolemia. The expression of various adhesion molecules for leukocytes 
probably triggers the first step in the recruitment of white blood cells to the sight 
of further lesions. After the adhesion some white blood cells will migrate into 
the intima. The direct migration of leukocytes probably depends on chemoattractant 
factors including modified lipoprotein particles and chemoattractant cytokines such as 
the chemokine macrophage, chemoattractant protein-1 produced by vascular wall cells 
in response to macrophage proteins. Leukocytes are seating permanently in the evolving 
fatty streak and can divide and exhibit augmented expression of receptors for modified 
lipoproteins-scavenger receptors. These mononuclear phagocytes soak the lipids 
and transform them into foam cells whose cytoplasm is filled with lipid droplets.  
FORMATION OF THE FIBROUS CAP AND LIPID CORE 
As the fatty streak extends into more complicated atherosclerotic lesions, smooth 
muscle cells accumulate within the expanding intima and the amount of extracellular 
matrix increases. The fibrous cap, formed of extracellular matrix elaborated 
by the smooth muscle cells in the intima, characteristically overlies a lipid core field 
with macrophages. In addition to dividing, these cells in the lipid core can die 
and release their lipid contents into the extracellular space.  
4
 (Fig. 1) 
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Fig. 1 Initiation and progression of atherosclerosis. Atherosclerosis occurs at sites in the arterial 
tree where laminar flow is disrupted. A lesions begins as a fatty streak (a) and can develop into 
an intermediate lesion (b), and then into a lesion what is vulnerable to rupture (c) and, finally, 
into an advanced obstructive lesion (d).  1 
An integral view of experimental results in animals and study of human 
atherosclerosis indicate that the fatty streak represents the initial lesion 
of atherosclerosis. This accumulation of lipoprotein particles may not simply come from 
an increased permeability of the overlying endothelium. These lipoproteins can be 
collected in the intima of arteries because they are bound to constituents 
of the extracellular matrix, increasing the residence time of the lipid-rich particles 
within the arterial wall. Lipoproteins accumulating in extracellular area of the intima 
of arteries often associate with proteoglycan molecules in the arterial extracellular 
matrix. This accumulation supports a pathogenic role for such modifications 
of lipoproteins in atherosclerosis.  
  2.1.3  Leukocyte Recruitment 
After the accumulation of extracellular lipid, recruitment of leukocytes occurs 
as a second phase in formation of the fatty streak. The white blood cell types that are 
typically found in the evolving atheroma comprise primarily cells of the mononuclear 
lineage-monocytes and lymphocytes. An amount of adhesion molecules or receptors 
for leukocytes expressed on the surface of the arterial endothelial cell likely participates 
in the recruitment of leukocytes to the nascent fatty streak. Adhesion molecules 
of particular importance include VCAM-1 vascular cell adhesion molecule and ICAM-1 
intercellular adhesion molecule and P-selectin. Expression of the gene encoding 
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the adhesion molecule CD44 is upregulated specifically in atherosclerotic lesions, 
and deletion of this gene results in reduced monocyte recruitment and less development 
of atherosclerosis. Laminar shear forces can also suppress the expression of leucocyte. 
Sites of predilection for forming atherosclerotic lesions often have disturbed laminar 
flow. Ordered laminar shear of normal blood flow extends the production of nitric oxide 
by endothelial cells. After the adhesion to the surface of the arterial endothelial cell 
through interaction with a receptor such as VCAM-1, the monocytes and lymphocytes 
penetrate the endothelial layer and settle down in the intima. In addition to products 
of modified lipoproteins, cytokines could regulate the expression of adhesion molecules 
involved in leukocytes recruitment. Modified lipoproteins could induce cytokine release 
from vascular wall cells; this pathway could provide an additional connection between 
accumulation and modification of lipoproteins and leukocyte recruitment. The regulated 
migration of leukocytes into the arterial wall could also result from the actions 
of modified lipoprotein. For example, oxidized LDL can promote the chemotaxis 
of leukocytes as well as oxidatively modified lipoproteins can elicit the production 
by vascular wall cells of chemoattractant cytokines such as monocyte chemoattractant 
protein 1(Mcp- 1). 
  2.1.4  Foam- cell formation 
Once the mononuclear phagocytes are settled in the intima they begin to divide 
into macrophages and transform into foam cells. Transformation of mononuclear 
phagocytes into foam cells requires the uptake of lipoprotein particles by receptor- 
mediated endocytosis. Supposedly it is recognized receptor for LDL that mediates this 
lipid uptake. Alternative receptors that can mediate lipid- loading of foam cells include 
a growing number of macrophage scavenger receptors, which primarily endocytose 
modified lipoproteins and other receptors for oxidized LDL or β-VLDL, a type 
of lipoprotein commonly encountered in certain hypercholesterolemic states. 
By sucking in lipids from the extracellular place, the mononuclear phagocytes carrying 
such scavenger receptors could remove lipoproteins from the developing lesions. Lipid 
accumulation is a significant supporter to creation of the atheroma. Macrophages could 
thus play a vital role in the dynamic economy of lipid accumulation in the arterial wall 
during atherogenesis. Macrophages taking up modified lipoproteins could design 
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cytokines and growth factors that can further signal some of the cellular events 
in lesions complication. An amount of growth factors or cytokines worked out 
by mononuclear phagocytes can stimulate smooth- muscle cell proliferation 
and production of extracellular matrix, which accumulates in atherosclerotic plaques. 
Examples of cytokines that can induce local production of growth factors that can play 
an important role in plaque evolution and complication are IL-1 and TNF-α. Other 
cytokines, namely interferon- γ derived from activated T-cells within lesions, can inhibit 
smooth- muscle proliferation and synthesis of interstitial forms of collagen. 
4
 
 
 2.2 Lipoprotein metabolism 
Lipoprotein transport lipids in the blood and their metabolism are closely 
interrelated with the initiation and progression of atherosclerosis. 
5
 Primarily are 
concerned LDLs and HDLs. HDL particles have anti-atherogenic properties due their 
ability to take up cholesterol from non hepatic cells and transport them back to the liver 
through the reverse cholesterol transport pathway. 
6
 HDL seems to have anti-
inflammatory and anticoagulatory properties. 
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The intestine absorbs dietary fat and packages it into chylomicrons, which are 
then transport to peripheral tissues through the blood. In adipose tissues and muscles, 
the enzyme lipoprotein lipase breaks down chylomicrons, and fatty acids enter these 
tissues. The rest of chylomicrons are subsequently taken up by the liver. The liver loads 
lipids onto apoB and secretes VLDLs, which undergo lipolysis by lipoprotein lipase 
to form LDLs. These LDLs are taken up by the liver through binding to the LDL 
receptor. HDLs are generated by the intestine and the liver through the secretion of lipid 
free apoA-I, which recruits cholesterol from these organs through the action 
of the transporters ABCA1, forming nascent HDLs, and this protects apoA-I from being 
rapidly degraded in the kidneys. Nascent HDLs promote the efflux of cholesterol 
from tissues through the actions of ABCA1. Mature HDLs promote this efflux through 
the actions ABCG1. In macrophages, the nuclear receptor LXR up-regulates 
the production of both ABCA1 and ABCG1. The free cholesterol in nascent HDLs is 
esterified to cholesteryl ester by the enzyme lecithin cholesterol acyltransferase LCAT, 
which creating mature HDLs. The cholesterol in HDLs is returned to the liver directly 
14 
 
through uptake by the receptor SRBI and indirectly by transfer to LDLs and VLDLs 
through the cholesteryl ester transfer protein CETP. The lipid involves of HDLs is 
altered by the enzymes hepatic lipase and endothelial lipase and by the transfer proteins 
CETP and phospholipid transfer protein PLTP, affecting HDL catabolism. 
1
 (Fig. 2) 
The lowering of LDL-cholesterol levels is one of the most important therapeutic 
targets that have been used to reduce cardiovascular morbidity and mortality. 
8
 
Optimization of strategies have recently focused to innovate approaches how to raise 
HDL-cholesterol levels. 
9,10
 The strong HDL- cholesterol elevating effect has nicotinic 
acid, which is unique among the drugs currently approved for clinical use. 
11
 
 
 
 
Fig. 2 Metabolism of lipid particles. Lipoprotein metabolism has a key role in atherogenesis; it 
involves the transport of lipids, particularly cholesterol and triglycerides, in the blood.  1 
 
2.3 Nicotinic acid 
Nicotinic acid and nicotinamide serve as precursors of coenzymes NAD 
and NADP and are water soluble vitamins of the vitamin B complex. 
12
 
Pharmacological doses of nicotinic acid induce a profound change in the plasma levels   
of various lipids and lipoproteins. The ability of nicotinic acid to strongly increase 
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the plasma concentrations of HDL and reduce the risk of cardiovascular events has 
in recent years led to an increased interest in the pharmacological potential of nicotinic 
acid. The clinical use of nicotinic acid is, however, hindered by harmless but unpleasant 
side effects, especially by a strong cutaneous vasodilatation called flushing. 
13,14
 
  2.3.1 Mechanism of action of nicotinic acid 
The recent discovery of the G-protein-coupled receptor GPR109A, also referred 
HM74A in humans and PUMA-G in mice, as a receptor for nicotinic acid has allowed 
for better understanding of the mechanisms underlying the metabolic and vascular 
effects of nicotinic acid. Through the use of mice lacking the gene coding 
for the receptor GPR109A was shown to be the receptor mediating the lipid-lowering 
effects of nicotinic acid. G-protein mediates many effects of nicotinic acid 
on adipocytes and immune cells. 
15,16,17
 
  2.3.2 GPR109A 
 GPR109A is a member of the class A rhodopsin-like GPCRs. GPR109A is 
also expressed at significant levels in the spleen and immune cells, such as monocytes, 
macrophages, neutrophils. 
15, 16, 17, 18
 Expression of GPR109A in immune cells 
appears to be regulated by various cytokines and can be upregulated by GM-CSF 
in neutrophils. 
19
   
 GPR109A has been shown to couple to members of the Gi family of G proteins, 
activation of Gi- type leads to different cellular effects depending on the type of cells. 
In immune cells Gi activation primarily results in the stimulation of β-isoform 
of phospholipase C or of phosphoinositide-3-kinase γ via G protein β, γ-subunits 
released from activated Gi, in other cells for example adipocytes, activation of Gi 
preferentially results in the inhibition of the activity of adenyl cyclase, resulting 
in a decrease in intracellular cyclic AMP levels. Protein kinase A phosphorylates 
a number of proteins especially hormone- sensitive lipase and perilipin, which are 
required for triacylglycerol hydrolysis. Phosphorylation of perilipin activates access 
to the TAG containing lipid droplets by the now activated hormone sensitive lipase 
and adipose triacylglycerol lipase, which hydrolyzes the triacylglycerols in to free fatty 
acids and glycerol. 
20
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  2.3.3 Effect of nicotinic acid on lipid metabolism 
 Oral administration of nicotinic acid causes a decrease in free fatty acids plasma 
levels, followed by a reduction in the concentration of VLDL triglycerides. 
21
 
 
 2.4 Immune cells in atherosclerosis 
 Atherosclerotic plaques contain blood-borne inflammatory and immune cells, 
mainly macrophages and T cells, then vascular endothelial cells, smooth muscle cells, 
extracellular matrix, lipids and acellular lipid-rich debris. 
22
 Accumulation of immune 
cells and lipid droplets in the intima occurs during the first phase of plaque formation.  
 Other cell types present in mature plaques include dendritic cells, mast cells, 
a few B cells and probably natural killer T cells. 
22,
 
23,
 
24
  
 Many of these immune cells activate and produce proinflammatory cytokines 
such as interferon-γ and tumour- necrosis factor. 25  
 
 2.5 Chemokines 
 Chemokines belong to a large group of structurally related chemotactic 
cytokines and they can be divided into 4 families based on the position of the first two 
cystein residues-CC, CXC, CX3C, and XC.  
 Within atherosclerotic plaques is their function as messengers to 
direct leukocytes to sites of inflammation and they can control homeostasis 
and other activities of emigrated cells. By signalling through G protein chemokines 
govern a variety of cell responses including cell activation and transmigration in 
leukocytes. 
26,27
 
 In addition to the expression of adhesion molecules, several chemokines 
produced by vascular cells guide the recruitment of immune cells.  
The key role in the initiation of atherosclerosis plays CC-chemokine ligand 
2 also known as MCP-1 and its receptor CC-chemokine receptor 2. 
28,
 
29
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 3 AIM OF WORK 
 
We have focused on: 
 Development of atherosclerosis in LDLR (low density lipoprotein receptor) 
deficient and LDLR, PumaG double deficient mice treated or untreated with nicotinic 
acid. 
 
In the second part of this work we have focused on: 
 Analyse of GPR109A expression in leukocyte with PU- REP mice by using 
methods bloodsmear and diff-quick staining. 
PUMA-G expression in vitro by stimulating thioglycolate, casein solution for induce 
of inflammation 
Concentration response relationship of cell signalling on the: 
- nicotinic acid (NA) 
- macrophage/monocyte chemotactic protein-1 (MCP-1) 
-  macrophage inflammatory protein-1-α (MIP-1-α) 
-  regulated upon activation, normal T cell expressed and presumably secreted 
(RANTES) 
- interleukin-8 (IL-8) 
by measuring intracellular calcium levels in the cell lines expressing of primary cell 
culture, cell culture line. 
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4  MATERIAL   
 4.1 Material 
Biozym pipette 20-200µl    Biozym, Hessig Oldendorf, GE 
Coverslip glasses, 24x60mm    Hartenstein, Heidelberg, GE 
Delimiting pen, Dako pen    Dako, USA 
Eppendorf pipettes     Eppendorf, Hamburg, GE 
Eppendorf tubes 1.5ml, 2ml    Eppendorf, Hamburg, GE 
Falcon tubes 15ml, 50ml    Becton Dickinson Labware, USA 
Falcon cell strainer 40 µm    Becton Dickinson Labware, USA 
Microtube 2ml     Sarstedt, Nümbrecht  
Needle 21, 27G     Braun, Melsungen, GE 
Pasteur capillary pipettes, 230mm   WU Mainz, GE 
Pipette tips      Brand, Wertheim, GE 
Polysine slides     Menzel, GE 
Scissors      FineScience Tools, Heidelberg, GE 
Sterile pipette 2ml, 5ml, 10ml, 25ml   Sarstedt, Nurmbrecht, GE 
Syringe 1ml, 20ml, 60ml    Becton Dickinson Labware, USA 
Tweezers      FineScience Tools, Heidelberg, GE 
 
4.2 Instruments 
Analytical balance     Scaltec, Göttingen, GE 
Autoclave- H1Clave-HV-85    HMC, Hong Kong 
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Cryotome Leica CM 3050S    Leica, GE 
Centrifuge 5810R     Eppendorf, GE 
Freezer -80°C      Brunswick, USA 
Incubator Hera cell 240    Heraeus, GE 
Laminar flow cabinet     Heraeus, GE 
Liquid nitrogen tank LS 4800   Taylor- Wharton, Husum, GE 
Mikroscope Zeiss Axiovert 25   Hitachi, USA 
Mikroscope Leica DM LS2    Leica, GE 
Ultracentrifuge Himac CS 100fx   Hitachi, USA 
Vortex       Heidolph genie 2, Heidelberg, GE 
Waterbath      Eppendorf, Hamburg, GE 
 
4.3 Chemicals 
Aceton      Zentralbereich Neuheimer Feld, GE 
Adsorbed rabbit anti- mouse macrophage AB Accurate, USA 
Biotinylated anti- rabbit IgG    Vector, CA 
Brewer thioglycollate medium   Sigma, GE 
Calcium chloride dihydrate    J.T.Baker, Deventer, Holland 
Casein sodium salt, from bovine milk  Sigma, GE 
D(+)- Glucose- monohydrate    Merck, Darmstadt, GE 
Dimethyl sulfoxide     AppliChem, Darmstadt, GE 
DMEM 1x      Gibco, GE 
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DPBS 1x, 10x      Gibco, GE 
Ethylene diamine tetraacetic acid   Roth, Karlsruhe, GE 
Foetal bovine serum     Gibco, GE 
Fura-2/AM      Molecular Probes, Invitrogen, GE 
FMLP       Sigma, GE 
Glycerol gelatine     Merck, Darmstadt, Ge 
GM-CSF      Sigma, GE 
Hematoxylin       Zentralbereich Neuheimer Feld, GE 
HEPES      Roth, Karlsruhe, GE 
Hydrogen peroxide 30 %    Sigma, GE 
Il-8       Sigma, GE 
Insulin, human recombinant zinc, solution  Gibco, GE 
L- Glutamine 200mM    Gibco, GE 
Magnesium chloride hexahydrate   AppliChem, Darmstadt, GE 
Mcp-1       Sigma, GE  
Mip-1-α      Sigma, GE 
Nicotinic acid      Sigma, GE 
NGS       Vector, CA 
Pen Strep, Penicilin Streptomycin   Gibco, GE 
Potassium chloride     AppliChem, Darmstadt, GE 
Rantes       Sigma, GE 
RPMI 1640      Gibco, GE 
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Sodium pentobarbital- Narcoren   Rhone Merieux, Laupheim, GE 
Sodium pyruvate 100mM    Gibco, GE 
Tissue freezing medium    Leica, GE 
Triton        Zentralbereich Neuheimer Feld, GE 
 
4.4 Kits 
ABC kit      Vector, CA 
AEC staining kit     Sigma, GE 
Diff quick staining set    Medion Diagnostics, GE 
 
4.5 Software  
Adobe Photoshop 7.0 
Adobe Photoshop CS3 
Microsoft Office 
Stereo Investigator 
Till Vision 
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5 METHODS 
 5.1 In vivo experiments 
  5.1.1 Animal experiments and development of    
  atherosclerosis 
Eight weeks old male LDLR deficient mice (group 012) and LDLR, PumaG 
double deficient mice (group 014) were used to study atherosclerosis. Animals of each 
strain were divided into two experimental groups and underwent high fat diet which 
contained 21% butter fat and 1.5% cholesterol ad libitum with or without 0.3% nicotinic 
acid in drinking water for 16 weeks. Mice were weighed and controlled every week.  
  5.1.2 Dissection of the heart 
Mice were anesthetized with 100 µl of pentobarbital i.p. and the depth 
of narcosis was controlled by pressing the sciatic nerve. After blood withdrawal 
by cardiac puncture the chest was opened, small incision was made in the right ventricle 
and the mouse was perfused through the left ventricle with 20ml PBS followed 
by 20 ml fixative 4% PFA, 20mM EDTA, 5% sucrose in PBS by using a perfusion 
pump. The upper half of the heart was cut and incubated in fixative and 30% sucrose 
at 4°C overnight, respectively. Afterwards the hearts were frozen in tissue medium 
and stored at -80°C until we cut them in a cryostat in sections of 8 µm.  
 Starting with the section where all three aortic valves were visible the sections 
were sequentially collected in a series of five slides. Slides were stored at -80°C until 
they stained. 
  5.1.3 Immunostaining 
 Slides were dried at room temperature for 30 minutes and made a circle around 
all sections with a delimiting dako pen. Sections were fixed on ice cold acetone 
for two minutes and permeabilized in PBST (PBS + 0.1% TRITON-X-100) 
for two minutes to remove freezing medium. Slides were washed two times 
for two minutes in PBS. To quench endogenous peroxidase slides were incubated 
in 0.3% H2O2 in PBS and then rinsed three times in PBS for 2 minutes. Sections were 
blocked with 5% NGS for 45 minutes at RT and then incubated with rabbit anti- mouse 
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macrophage antibody at 1:100 dilution in 5% NGS at 4°C overnight. Afterwards slides 
were washed three times for two minutes in PBS and incubated with biotinylated goat 
secondary anti- rabbit IgG antibody in 1:200 dilution in 5% NGS for 30 minutes at RT. 
Slides were washed three times for 2 minutes in PBS. To localize peroxidase in sections 
ABC reagent, which consists of 2.5 ml PBS with 1 drop A + 1 drop B, was used 
and slides were incubated for 30 minutes in the humid chamber. Then slides were rinsed 
two times in PBS for two minutes and then were slides dipped in AEC reagent 
for five minutes, which consists of 4 ml H2O with 2 drops Acetate and 1 drop AEC + 1 
drop H2O2. After that slides were immersed in distillated H2O for five minutes, 
then in acidic water for 20 seconds, counterstained in hematoxylin for five minutes 
and finally slides were rinsed under cold tap water for five minutes. Then I dried slides 
and covered them with warmed up glycerol gelatin.  
 Negative control underwent the same treatment except of incubation 
with primary antibody which was replaced by 5% NGS.  
  5.1.4 Quantification of atherosclerosis  
 Stained sections in 50x magnification were photographed in a microscope. 
To evaluate the percentage of lesion/plaque area in the aortic valve and the percentage 
of immunostained macrophages in lesion/ plaque lesion area measurements were 
performed on each slide with image analysis software Adobe Photoshop CS3 by using 
a magnetic lasso tool. There was manually traced the outline of the region of the aortic 
valve, of the plaque, respectively and red stained macrophages. The number of pixels 
was. Data were imported into Microsoft Excel which was used for statistical evaluation. 
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5.2 In vitro experiments 
  5.2.1 Animals 
 Mice lacking PUMA-G–knockout mice and wildtype mice were taken 
from breed of our institute. Mice were injected with 4% thioglycolate and treated 
from two to five days or with casein solution over night.  
 Granulocyte-macrophage colony stimulating factor (GM-CSF) is growth factor, 
stimulating proliferation, which was used to enhance cells adherence to glass cover 
slips.  
  5.2.2 Peritoneal lavage 
Mouse was euthanized by carbon dioxide to asphyxiation. After cleaning 
the abdomen with 70% ethanol, was made a ventral midline incision and retracted 
abdominal skin to expose peritoneal wall. Mice were injected with 10 ml 5mM EDTA 
in PBS into the peritoneum. The abdomen was massaged and slowly withdrew 
the peritoneal fluid. This step was repeated with 5 ml dPBS. Peritoneal fluid was 
filtrated through 40 µm cell strainer into a 50 ml conical tube and was centrifuged 
ten minutes at 1000 rpm at 4°C. The supernatant was removed and cell pellet was 
resuspended cell in PBS medium for subsequent staining with Diff Quick or in RPMI 
1640 medium for subsequent measurement of intracellular calcium.   
  5.2.3 Staining with Diff Quick 
 It was made a drop of 5-10 µl of cell suspension on the lower part of a slide. 
Then the cells were smeared with using spreader slide under the angle of 45°C 
to disperse the cells over the slide's length. The slides were left to air dry. To fix 
the smear the methanolic fixative solution was used to stabilize cellular components. 
Solutions I and II were then applied individually to the fixed smear to differentially 
stain specific cellular components. Every slide was dipped in fixative solution five 
times, one second each time. It was allowed to excess to drain. Then was every slide 
dipped in solution I five times, one second each time and finally the same process was 
repeated with solution II. Then all slides were washed with distilled water and left 
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to dry. Stained slides in 400x magnification were photographed in a microscope 
with normal vision and fluorescence to find expression of gene.  
  5.2.4 Isolation of peritoneal neutrophils 
Mouse was injected with 1 ml of casein solution (9 g of casein compound 
with stirring 10 ml PBS 80
o 
C to 90
o 
C, pH 7.2 containing 0.9mM CaCl2  and 0.5mM 
MgCl2). Solution was brought to a boil and then autoclaved one hour at 125
o 
C) 
into peritoneal cavity of mouse, to induce inflammatory response. The injection of 1 ml 
casein solution was repeated next morning. Three hours after the second injection, 
the mouse was euthanized by carbon dioxide asphyxiation. It was made a ventral 
midline incision with scissors and then retracted abdominal skin with forceps to expose 
the intact peritoneal wall. After cleaning abdomen with 70% ethanol was injected 5 ml 
of sterile 5mM EDTA in PBS solution into the peritoneum. The abdomen was massaged 
gently to distribution of the harvest solution. The peritoneal fluid was slowly withdrawn 
and transferred into a 50 ml conical tube. It was injected another 5 ml of sterile 5mM 
EDTA in PBS solution and repeated the procedure to remove the remaining cells from 
the peritoneum and transfer them to the tube. Peritoneal fluid was filtrated through 40 
µm cell strainer into a tube and it was centrifuged ten minutes at 200 rcf at room 
temperature. Then the supernatant was removed and the peritoneal exudates cells were 
washed three times, each time were the cells resuspended in 10 ml of PBS and 
centrifuged. The washed pellet was resuspended in 1 ml sterile PBS, the number of 
viable cells was counted by trypan blue. It was mixed 3-5x 10
7
 peritoneal exudates cells 
with 9 ml Percoll gradient solution(5 ml sterile PBS, ph 7.2 in 45 ml sterile Percoll) at 
room temperature in a 5 ml Beckman ultracentrifuge tubes. Peritoneal fluid was 
ultracentrifuged 20 min at 26 000 rpm at 4
o 
C. Then the thin, faint upper layer was 
discarded, which contained macrophages and lymphocytes and it was collected 
the PMN- polymorphonuclear leukocytes, which were found in the second opaque 
layer. The bottom layer contained erythrocytes. Cells were washed by adding 10 ml 
of PBS and centrifuged five minutes at 200 rcf at room temperature. The supernatant 
was removed, the pellet was resuspended in 1 ml medium DMEM, containing 2mM 
Glutamine + 10% FBS. 
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  5.2.5 Isolation of neutrophils from peripheral blood 
 Mouse was anesthetized by injecting 100 µl Phenobarbital, it was drawn 5 µl 
of EDTA into 1 ml syringe with 21-G needle, then syringe was used to bleed mice 
by cardiac puncture, blood was transferred to 1.5 ml Epi. The blood was centrifuged ten 
minutes at 200 rcf in a tabletop centrifuge at room temperature, then the whitish buffy 
coat layer, which appears at the plasma interface was collected, cells were counted, it 
was resuspended 3-5 x 10
7 
cells in 1 ml of PBS added 9 ml Percoll gradient solution 
at room temperature in a 5 ml Beckman ultracentrifuge tubes. Cells were 
ultracentrifuged the 20 min at 26 000 rpm at 4
o
C. Then the thin, faint upper layer, which 
contained macrophages and lymphocyte, was discarded and the PMN- 
polymorphonuclear leukocytes, which were found in the second opaque layer, were 
collected.  
  5.2.6 Primary cell culture 
  The glass cover slips (24-mm round #1 glass) were placed in 6-well culture 
plates. After the isolation from mice were peritoneal exudates cells, peritoneal 
neutrophils, blood neutrophils diluted in medium. The drops of cells were made 
on an average around 150 μl and were localized to the middle of the cover slips. 
The medium contained 20nM GM-CSF. Cells were incubated overnight. In the morning 
the cells were washed with used medium. 
   
  5.2.7 Cell culture lines 
THP-1(cell type: human acute monocytic leukemia) 
 Developed from the peripheral blood of 1 year old boy with acute monocytic 
leukemia at relapse in 1978, the cells were described to produce lysozyme and to be 
phagocytic.  
The cells were cultivated at 37
o
C with 5% CO2 in medium 90% RPMI 1640, 
containing 10% FBS, supplemented with 50 units/ml penicillin and 50 mg/ ml 
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streptomycin. The cells were maintained at 0.1-1.0 10
6 
cells/ml, splitted them 1:2 every 
3-4 days. The cells were round, single cells in suspension, partly in clusters.  
Cells defrosting 
 The ampoule with cells was thawed in a water bath (37°C) and the cells were 
transferred into a 15 ml centrifuge tube with adding 10 ml prewarmed medium 
and mixed gently. The cells were centrifuged at 1000 rpm at 24°C for five minutes. 
The supernatant was decanted, the cells were resuspended in a defined volume 
of medium, there was removed a small sample in order to determine cell number 
and viability. For the first couple of days after recovery was used higher concentration 
of FBS (15%).  
Cell counting 
 Neubauer counting chamber 
 To determine the number of living cells, a probe from cells solution was taken, 
diluted 1:10 in trypan blue and counted in Neubauer counting chamber. Trypan blue 
deposits in cell protein structures, but can enter only permeable cell membranes 
and thus stains dead cells only. The final cell count can be calculated:  
 Cells/ ml = cell count from four small quadrants x dilution x chamber 
constant (10
4
). 
Cell frosting  
 Eukaryotic cells were stored in liquid nitrogen. To freeze the cells, pellets were 
placed in freeze medium and resuspended to 1 ml of 5x10
6
 –1x107 cells. The especially 
microtubes were transferred into liquid nitrogen tanks. 
 
  5.2.8 Measurement of intracellular calcium 
For the measurement of intracellular calcium cells were seeded on cover slip 
glasses (24 x 60 mm) placed in 6-well plate with medium consisting 20nM GM-CSF 
overnight to induce differentiation into macrophages and thereby adherence. The no 
adherent cells were removed by washing with Hank´s balanced salt solution (HBSS) 
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containing calcium ions. All experiments were performed at temperature 37
o
C. 
The cells placed on cover slips were incubated in modified HBSS solution containing 
reduced calcium (2mM CaCl2) and pluronic F-127 (0.01%) as a detergent and Fura-2 
AM (5mM) for 60 min in the dioxide incubator. After loading, preparations were 
superfused with HBSS solution, containing 2mM CaCl2. Cover slips were then removed 
from the culture plates and mounted into a chamber with adding 600 μl buffer HBSS 
with Ca ions. Buffer HBSS consists of 120mM NaCl, 5.4 mM KCl, 0.8mM 
MgSO4.7H20, 10mM HEPES, 2mM CaCl2.2H2O. The agonists were added after 50-
100sec. Negative control experiments were performed by using buffer, positive control 
experiments using FMLP. Used agonists were NA, MCP-1, MIP-1-α, IL-8, RANTES. 
Fluorescence excitation was measured at 340 and 380 nm light (F340/380), emission 
recorded at 510 nm. Fluorescence emission from a region of the loaded cells was 
recorded at 30 Hz, with a photometry system T.I.L.L. Photonics and pCLAMP 8 
software Axon Instruments.  (Fig. 3) 
 
 
 
 
 
 
 
 
 Fig. 3 Peritoneal exudates cells stained with Fura-2 before stimulation of agonists 
29 
 
6 RESULTS 
6.1 In vivo experiments 
  6.1.1 Heart section  
  
 The following pictures show (Fig.4-Fig.21) 8 µm sections of heart 
immunostained with antibody against macrophages.  
 The difference between two following sections is 40 µm, usually. The aortic 
valve opens up gradually and quantity of plaque increases.  
 
 Images were made in the program Stereo investigator by using Leica 
microscope, by 50x magnification, intensity 5.  
Hearts were divided into two groups: 
- 012 – LDLR k.o.  - hearts 11-15 only high fat diet- control 
 
   - hearts 16-20 high fat diet + 0.3% nicotinic acid 
 
- 014- PumaG double deficient - hearts 1-3 only high fat diet- control 
     - hearts 4-6 high fat diet + 0.3% nicotinic acid 
We compared percentage area of plaque and macrophages
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Fig. 4 Heart section 1-4 of  LDLR deficient mice with high fat diet without nicotinic acid 
 
 
 
 
 
 
 
Fig. 5 Heart section 1-4 of  LDLR deficient mice with high fat diet without nicotinic acid 
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Fig. 6 Heart section 5-8 of  LDLR deficient mice with high fat diet without nicotinic acid 
 
 
 
 
 
 
 
 
Fig. 7 Heart section 5-8 of  LDLR deficient mice with high fat diet without nicotinic acid 
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Fig. 8 Heart section 9-11 of  LDLR deficient mice with high fat diet without nicotinic acid 
 
 
 
 
 
Fig. 9 Heart section 9-10 of  LDLR deficient mice with high fat diet without nicotinic acid 
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Fig. 10 Heart section 1-4 of  LDLR deficient mice with high fat diet with 0,3% nicotinic acid 
 
Fig. 11 Heart section 1-4 of  LDLR deficient mice with high fat diet with 0,3% nicotinic acid 
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Fig. 12 Heart section 5-8 of  LDLR deficient mice with high fat diet with 0,3% nicotinic acid 
 
Fig. 13 Heart section 5-8 of  LDLR deficient mice with high fat diet with 0,3% nicotinic acid 
 
35 
 
 
Fig. 14 Heart section 9-12 of  LDLR deficient mice with high fat diet with 0,3% nicotinic acid 
 
Fig. 15 Heart section 13-16 of  LDLR deficient mice with high fat diet with 0,3% nicotinic acid 
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Fig. 16 Heart section 1-4 of  LDLR  PumaG double deficient mice e with high fat diet without 
nicotinic acid 
 
Fig. 17 Heart section 5-8 of  LDLR  PumaG double deficient mice e with high fat diet without 
nicotinic acid 
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Fig. 18 Heart section 9-12 of  LDLR  PumaG double deficient mice e with high fat diet without 
nicotinic acid 
 
Fig. 19 Heart section 1-4 of  LDLR  PumaG double deficient mice e with high fat diet with 
0,3% nicotinic acid 
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Fig. 20 Heart section 5-8 of  LDLR  PumaG double deficient mice e with high fat diet with 0,3% 
nicotinic acid 
 
 
Fig. 21 Heart section 9-12 of  LDLR  PumaG double deficient mice with high fat diet without 
nicotinic acid 
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6.1.2. Quantification of atherosclerosis 
 
  control 0.3% NA 
LDLR 18.5 17.5 
PumaG.LDLR 17.5 18.1 
   
  Control 0.3% NA 
LDLR 9.4 7.9 
PumaG.LDLR 3.4 1.8 
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Fig. 22 Quantification of plaque all sections  
 First we evaluated the total area of plaque in the aortic valve at all slides 
and compared control group with the group, who were added nicotinic acid 
in the drinking water and then red stained macrophages in the plaque.  
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  control 0.3% NA 
LDLR 29.3 28.9 
PumaG.LDLR 27.3 24.4 
   
  Control 0.3% NA 
LDLR 10.5 6.0 
PumaG.LDLR 2.5 2.9 
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Fig. 23 Quantification of macrophages all sections 
 
 As one can see from the diagrams (Fig.22, Fig.33) as expected, unfortunately we 
didn’t observe the difference between untreated group (control) and treated group 
with 0.3% nicotinic acid, which is ultimately not so surprising because between both 
groups we didn’t see neither difference between the plaque.  
 In the summary this experiment the groups of interest were too small and it is 
to see higher values of standard deviation. The experiment should be repeated with a 
larger number of mice in group. 
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6.2 In vitro experiments 
  6.2.1 Cell smear 
    BLOOD CELLS 
 
Fig. 24 The effect of blood cells obtained per eye, the retro-orbital bleeding from wildtype mice, 
directly stained with Diff- Quick staining.  
 
 
 
 Blood cells (Fig.24) obtained per eye, the retroorbital bleeding placed on glass 
slides were stained with Diff Quick method as described 5.2.3. There occurred number 
of: Erythrocytes, Lymphocytes, Monocytes, Neutrophils, Basophils, Eosinophils 
and Platelets.  
 When we changed conditions for example. without staining, erythrocyte lysis, 
we have never seen positive fluorescence. Result was no expression of GPR109A in 
blood.  
 To determine the optimal timing for imaging fluorescence images were obtained 
maximal one hour past staining and protected before light. 
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   PERITONEAL EXUDATE CELLS 
Peritoneal macrophages 400x magnification (Fig. 25- Fig.29) 
 
 
 
 
  
Fig. 25 The effect of peritoneal exudates cells obtained from knockout mice PU- REP, which was 4 
days before injected with 4% thioglycolate i.p. to evoke inflammation. This figure shows positive 
fluorescence after thioglycolate stimulation. 
Fig. 26 The effect of peritoneal exudates cells obtained from knockout mice Puma-reporter, which 
was 4 days before injected with 4% thioglycolate i.p. to evoke inflammation. This figure shows 
positive fluorescence after thioglycolate stimulation. 
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     Fig. 28 The effect of peritoneal exudates cells obtained from knockout mice Puma-reporter,     
 which was 4 days before injected with 4% thioglycolate i.p. to evoke inflammation. This 
 figure shows positive fluorescence after thioglycolate stimulation. 
 
Fig. 27 The effect of peritoneal exudates cells obtained from knockout mice Puma-reporter, 
which was 4 days before injected with 4% thioglycolate i.p. to evoke inflammation. This figure 
shows positive fluorescence after thioglycolate stimulation. 
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 As one can see from the picture above (Fig. 25- Fig.29) gene GPR109A is 
expressed in peritoneal exudates, by inflammation state are more cells expressed 
as shown fluorescence microscopy. 
 
Fig. 29 The effect of peritoneal exudates cells obtained from knockout Puma-reporter mice, 
naïve without inflammation. This figure shows less expressed cells as during inflammatory state. 
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    BLOOD NEUTROPHILS  
 
 
Blood .NEUTROPHILS 
 
 The neutrophils were prepared as described in the Methods 5.2.5 and stained 
with Diff- Quick staining, subsequently. The cells were observed directly under 
a fluorescence microscope. As one can see from the picture (Fig.30) this data show no 
expression of gene GPR109A in the blood. 
 
Fig. 30 Blood neutrophils obtained from Puma-reporter mice injected with casein solution to 
evoke inflammation. On the left side evaluating under microscope by 200x magnification, in the 
right side under fluorescence, no expression of gene GPR109A.  
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 6.2.2 Calcium measurement 
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Fig. 31 The effect of 100µM nicotinic acid and 10nM macrophage/ monocyte chemotactic protein-1, 
subsequently on calcium signal in Fura-2-loaded peritoneal exudates cells from wildtype mice, which was 
2 days injected with 4% thioglycolate to induce inflammation. The Fura-2 interacted with cells 45 minutes. 
The figure shows the time course of a response at a fluorescence ratio of 340/380.  Nicotinic acid increased 
intracellular calcium by all marked cells, no changes past adding mcp-1. 
 The cells were loaded in medium containing 20nM GM-CSF overnight to enhance their 
adherence. The measurement was performed in 6-well plate. Individual cover slips were placed 
into chamber heated on 37°C with 600 µl HBSS medium contains Ca ions. 
  Negative control experiments were performed using buffer, positive control 
experiments using FMLP. 
 Values on the x axis indicate agonist concentration and values on the y axis indicate 
the measured 340/380 nm fluorescence ration as an indicator for the intracellular-free [Ca
2+
]i. 
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Fig. 32 The effect of 100µM nicotinic acid and 10nM macrophage/ monocyte chemotactic protein-1, 
subsequently on calcium signal in Fura-2-loaded peritoneal exudates cells from wildtype mice, which was 2 days 
injected with 4% thioglycolate to induce inflammation. The cells were loaded in medium containing 20nM GM-
CSF overnight to enhance their adherence. The Fura-2 interacted with cells 90 minutes. The figure shows 
the time course of a response at a fluorescence ratio of 340/380. All cells marked cells reacted on positive 
control. 
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Fig. 33 The effect 1 ng/ml RANTES on calcium signal in Fura-2-loaded peritoneal exudates cells from wildtype 
mice, which was 2 days injected with 4% thioglycolate to induce inflammation. The cells were loaded in medium 
containing 20nM GM-CSF overnight to enhance their adherence. The Fura-2 interacted with cells 60 minutes. 
The figure shows the time course of a response at a fluorescence ratio of 340/380. All marked cells reacted 
on positive control, no one on chemokine RANTES; in this figure is quiet large noise. 
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Fig. 34 The effect of 1 ng/ml RANTES on calcium signal in Fura-2-loaded peritoneal exudates cells from wildtype 
mice, which was 2 days injected with 4% thioglycolate to induce inflammation. The cells were loaded in medium 
containing 20nM GM-CSF overnight to enhance their adherence. The Fura-2 interacted with cells 70 minutes. 
The figure shows the time course of a response at a fluorescence ratio of 340/380. In this figure is opinion of reaction 
on positive control, but the noise is large and cells are not detectable.  
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Fig. 35 The effect of 10nM macrophage/ monocyte chemotactic protein-1 on calcium signal in Fura-2-loaded 
peritoneal exudates cells from wildtype mice, which was 2 days injected with 4% thioglycolate to induce 
inflammation. The cells were loaded in medium containing 20nM GM-CSF overnight to enhance their 
adherence. The Fura-2 interacted with cells 70 minutes. The figure shows the time course of a response at a 
fluorescence ratio of 340/380. All cells marked cells reacted on positive control, no one cell reacted on 
chemokine mcp-1. The red line could not be taken for detectable because gives response on negative control.  
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Fig. 36 The effect 10nM macrophage/ monocyte chemotactic protein-1 on calcium signal in Fura-2-loaded 
peritoneal exudates cells from wildtype mice, which was 2 days injected with 4% thioglycolate to induce 
inflammation. The cells were loaded in medium containing 20nM GM-CSF overnight to enhance their 
adherence. The Fura-2 interacted with cells 90 minutes. The figure shows the time course of a response at 
a fluorescence ratio of 340/380.   Most of marked cells reacted on positive control. 
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Fig. 37 The effect of 10nM macrophage/ monocyte chemotactic protein-1 on calcium signal in Fura-2-loaded 
peritoneal exudates cells from wildtype mice, which was 2 days injected with 4% thioglycolate to induce 
inflammation. The cells were loaded in medium containing 20nM GM-CSF overnight to enhance their adherence. 
The Fura-2 interacted with cells 80 minutes. The figure shows the time course of a response at a fluorescence ratio 
of 340/380. All marked cells didn’t give response on positive control, it is possible they were contaminated or death 
during measurement.  
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Fig. 38 The effect of 10nM macrophage/ monocyte chemotactic protein-1 on calcium signal in Fura-2-loaded 
peritoneal exudates cells from wildtype mice, which was 3 days injected with 4% thioglycolate to induce 
inflammation. The cells were loaded in medium containing 20nM GM-CSF overnight to enhance their 
adherence. The Fura-2 interacted with cells 45 minutes. The figure shows the time course of a response 
at a fluorescence ratio of 340/380. The cell- dark green line responded on mcp-1, but didn’t react on positive 
control, other cells reacted on positive control, and the noise is also large. 
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Fig. 39 The effect of 1µg/ml Interleukin-8 on calcium signal in Fura-2-loaded peritoneal exudates cells from 
wildtype mice, which was 3 days injected with 4% thioglycolate to induce inflammation. The cells were loaded 
in medium containing 20nM GM-CSF overnight to enhance their adherence. The Fura-2 interacted with cells 
55minutes. The figure shows the time course of a response at a fluorescence ratio of 340/380. All marked cells 
responded on positive control, no one on chemokine interleukin-8. 
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Fig. 40 The effect of 500ng/ml macrophage inflammatory protein-1-α on calcium signal in Fura-2-loaded 
peritoneal exudates cells from wildtype mice, which was 3 days injected with 4% thioglycolate to induce 
inflammation. The cells were loaded in medium containing 20nM GM-CSF overnight to enhance their 
adherence. The Fura-2 interacted with cells 80minutes. The figure shows the time course of a response 
at a fluorescence ratio of 340/380.  The several number of cells increased concentration of intracellular 
calcium past adding mip-1-α and also reacted on positive control. 
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Fig. 41 The effect of 500 ng/ml macrophage inflammatory protein-1-α on calcium signal in Fura-2-loaded 
peritoneal exudates cells from wildtype mice, which was 3 days injected with 4% thioglycolate to induce 
inflammation. The cells were loaded in medium containing 20nM GM-CSF overnight to enhance their adherence. 
The Fura-2 interacted with cells 90 minutes. The figure shows the time course of a response at a fluorescence ratio 
of 340/380. All marked cells reacted on chemokine mip-1-α and also on positive control. 
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Fig. 42 The effect of 500ng/ml macrophage inflammatory protein-1-α on calcium signal in Fura-2-loaded THP-1 
cell lines. The cells were loaded in medium containing 20nM GM-CSF for 6hours to enhance their adherence. 
The Fura-2 interacted with cells 80 minutes. The figure shows the time course of a response at a fluorescence ratio 
of 340/380. One cells- the red line reacted on chemokine mip-1-α and also on positive control.    
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Fig. 43 The effect of 500 ng/ml macrophage inflammatory protein-1-α on calcium signal in Fura-2-loaded THP-
1 cell lines. The cells were loaded in medium containing 20nM GM-CSF for 6hours to enhance their adherence. 
The Fura-2 interacted with cells 95 minutes. The figure shows the time course of a response at a fluorescence 
ratio of 340/380. No cells reacted on chemokine mip-1-α and two of them increased intracellular concentration 
of calcium on positive control.  
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Fig. 44 The effect of 100µM nicotinic acid and 1 µg/ml Interleukin-8, subsequently on calcium signal in Fura-2-
loaded blood neutrophlis from wildtype mice, which was 2 days injected with 4% thioglycolate to induce 
inflammation. The cells were loaded on polylysine coated cover slips to enhance their adherence. The Fura-2 
interacted with cells 55 minutes. The figure shows the time course of a response at a fluorescence ratio of 340/380. 
The cells- brown and blue line showe response on nicotinic acid and also on positive control, the cell- red one 
response in chemokine interleukin-8. 
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Fig. 45 The effect of 100µM nicotinic acid and 10nM macrophage/ monocyte chemotactic protein-1, subsequently on 
calcium signal in Fura-2-loaded blood neutrophlis from wildtype mice, which was 2 days injected with 4% 
thioglycolate to induce inflammation. The cells were loaded on polylysine coated cover slips to enhance their 
adherence. The Fura-2 interacted with cells 70 minutes. The figure shows the time course of a response 
at a fluorescence ratio of 340/380. The cells- red and blue line showed response on nicotinic acid and also on positive 
control, the cell- green one couldn’t be taken as detectable. 
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 The cells were prepared as described in the Methods 5.2.5. The cells were loaded with 
Fura-2 on polylysine coated cover slips to enhance their adherence and directly measured. 
The viability of neutrophils is short. 
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Fig. 46 The effect of 100µM nicotinic acid and 1 ng/ml RANTES, subsequently on calcium signal in Fura-2-
loaded peritoneal neutrophils obtained from wild type mice. The fura-2 interacted with cells 80 minutes. 
The figure shows the time course of a response at a fluorescence ratio of 340/380. Four marked cells reacted 
on nicotinic acid, no cells on RANTES. 
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 The cells were prepared as described in the Methods 5.2.5. The cells were loaded with 
Fura-2 on polylysine coated cover slips to enhance their adherence and directly measured. 
The viability of neutrophils is short. 
 
 As one can see from the charts above (Fig. 31- Fig. 47), used cells whether the 
peritoneal cells, neutrophils or cell lines THP-1 had reproducible response on nicotinic acid 
and positive control. We never confirmed repeatable response of any chemokine. We 
expected decreased concentration of used chemokine past adding nicotinic acid, which was no 
proven.
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Fig. 47 The effect of 100µM nicotinic acid and 10nM macrophage/ monocyte chemotactic protein-1, subsequently 
on calcium signal in Fura-2-loaded peritoneal neutrophils obtained from wild type mice.  The Fura-2 interacted 
with cells 90 minutes. The figure shows the time course of a response at a fluorescence ratio of 340/380. Nicotinic 
acid increased concentration of calcium and is visible some response to mcp-1 (the green line), it is also possible it 
cloud be some interruptions during measurement.  
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7 DISCUSSION 
  
 Atherosclerosis of the coronary arteries commonly causes angina pectoris 
and myocardial infarction. Atherosclerosis of the arteries supplying the CNS frequently 
provokes strokes and transient cerebral ischemia. Atherosclerosis causes intermittent 
claudication and gangrene. Also it can jeopardize limb viability, in the peripheral circulation. 
Atherosclerotic lesions often form regions of disturbed blood flow at branching points 
of arteries. 
4
 
 The increase in HDL-cholesterol levels, especially in patients with low levels, is one 
of the major strategies currently pursued. The oldest antidyslipidemic drug, nicotinic acid, 
remains the best choice for increasing HDL-cholesterol plasma levels. The recent discovery of 
a receptor for nicotinic acid has allowed new insight into the mechanisms underlying 
the pharmacological effects of nicotinic acid. 
13
 
 Most notably, nicotinic acid is able to raise plasma HDL cholesterol levels. Using 
a mouse mutant lacking the newly discovered receptor study research groups in Institute 
of Pharmacology  in Heidelberg, Germany. They are currently analysing its role as a potential 
mediator of wanted and unwanted pharmacological effects of nicotinic acid like HDL 
cholesterol increases, anti-atherosclerotic effects as well as peripheral vasodilatation called 
flushing. 
13
 
The idea that elevated HDL protects against coronary heart disease comes primarily 
from epidemiological studies.  
Novel agents being developed for regulating HDL metabolism include inhibitors of 
CETP and stimulators of the ABCA1 transporter CETP inhibitors can increase plasma HDL-
cholesterol by 60 % and lower LDL-cholesterol by 30 %. 
 The epidemiological, experimental and clinical trial evidence suggests that there is 
a good rationale for raising HDL-cholesterol in these and other high-risk patients. 
The protective effect of HDL-cholesterol against atherosclerosis and cardiovascular disease is 
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mediated by both enhanced reverse cholesterol transport and by direct anti-atherosclerotic 
mechanisms. The first approach to raising HDL-cholesterol in at risk patients is lifestyle 
modification aimed at improving body weight and insulin resistance. The currently available 
statins will often require adjunctive therapy, such as gemfibrozil or fish oil, to raise HDL-
cholesterol. Statin-fibrate combinations need to be monitored closely for risk of myositis. 
However, there is still more research to be done, including, for example, elucidating the 
precise molecular mechanism of the athero-protective effect of HDL and the developing and 
testing of new clinical therapies for improving HDL metabolism. The incremental benefit of 
adding a fibrate, fish oils or ‘pipeline agents’, such as CETP inhibitors (cholesterylester 
transfer protein), to a statin in low HDL patients with the metabolic syndrome are clearly 
burning questions for future clinical endpoint trials. 
30
 
 Nicotinic acid is the most effective agent available for increasing high-density 
lipoprotein-cholesterol, but its use is associated with side effects that negatively affect patient 
compliance: these appear to arise largely as a result of production of prostaglandin D(2) and it 
is subsequent activation of the DP(1) receptor. Desire to reduce the side effects (and improve 
pharmacokinetic parameters) has led to the development of a number of agonists that have 
differing effects, both in terms of clinical potency and the severity of adverse effects. 
31
 
Niacin was found to inhibit lipolysis in adipocytes and reported as early as 1960 
by Butcher, who investigated its effect on cyclic AMP. The investigators also found 
that niacin inhibits cyclic AMP production in epinephrine (adrenaline)-exposed adipocytes. 
Later work suggested the presence of a G-protein-coupled cell surface receptor of the Gig/Go 
type. In 2003, the nicotinic acid receptor was identified as the human orphan receptor HM74 
or the highly homologous, higher affinity HM74A, as well as the mouse homolog PUMA-G 
(protein upregulated in macrophages by interferon-[gamma]). HM74A (GPR109A) 
and PUMA-G are also identified as the pharmacologically active niacin receptors. 
The receptors mediate inhibition of adenyl cyclase in adipocytes and thereby block lipolysis, 
accounting for the marked reduction of free fatty acids caused by niacin. Furthermore, there 
was an approximately 30% reduction in triglycerides in fat-fed normal mice. In receptor-
deficient mice, no reductions in plasma free fatty acid and triglyceride levels were seen. 
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Substantial mRNA expression of HM74A/PUMA-G was found in brown and white adipose 
tissue, spleen, adrenal, and lung, but expression was essentially absent in liver. 
32
 
Nicotinic acid has been used for almost 50 years as a lipid-lowering drug. Its primary 
action is to decrease lipolysis in adipose tissue by inhibiting hormone-sensitive triglyceride 
lipase. This anti-lipolytic effect of nicotinic acid involves the inhibition of cyclic adenosine 
monophosphate (cAMP) accumulation in adipose tissue through a G(i)-protein-mediated 
inhibition of adenylyl cyclase. A G-protein-coupled receptor for nicotinic acid has been 
proposed in adipocytes. G-protein-coupled receptor, 'protein upregulated in macrophages 
by interferon-gamma' (mouse PUMA-G, human HM74), is highly expressed in adipose tissue 
and is a nicotinic acid receptor. Binding of nicotinic acid to PUMA-G or HM74 results 
in a G(i)-mediated decrease in cAMP levels. In mice lacking PUMA-G, the nicotinic acid-
induced decrease in free fatty acid (FFA) and triglyceride plasma levels was abrogated, 
indicating that PUMA-G mediates the anti-lipolytic and lipid-lowering effects of nicotinic 
acid in vivo. The identification of the nicotinic acid receptor may be useful in the 
development of new drugs to treat dyslipidemia. 
15
 
 Extended-release nicotinic acid)/laropiprant is a once-daily fixed-dose combination 
tablet that has been evaluated (with or without an HMG-CoA reductase inhibitor [statin]) 
in the treatment of adults with dyslipidaemia or primary hypercholesterolaemia. Nicotinic 
acid is a lipid-modifying drug and laropiprant is an anti-flushing agent, which reduces 
flushing induced by niacin. 
33
 
 Genetically modified mouse models have been instrumental in elucidating 
the underlying molecular mechanisms in lipid metabolism. 
34
 
 Wildtype mice are quite resistant to atherosclerosis as a result of high levels 
of antiatherosclerotic HDL and low levels of proatherogenic LDL and VLDL.  
 LDL receptor deficient mouse (LDLr
-/- 
mice), in which atherosclerosis develops 
especially when fed a lipid-rich diet. In humans, mutation in the gene for the LDL receptor 
cause familial hypercholesterolemia. Mice lacking the gene for LDL receptor develop 
atherosclerosis. 
35
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Experiment with two monitored groups of mice- LDLR (012) treated with 0.3% 
nicotinic acid and untreated control group and PumaG LDLR (014) treated with 0.3% 
nicotinic acid and untreated control.  
 We have tested the effect of nicotinic acid in the earlier mentioned groups of mice 
and found that the antiatherosclerotic effect was gone even tough in wildtype mice that was 
preserved and the lipid profile was not changed. The groups of mice were too small and it is 
to see higher values of standard deviation. The experiment should be repeated with a larger 
number of mice in group.  
To investigate the physiological expression of the PumaG receptor, a PumaG reporter 
mouse was developed. It expresses the mRFP (monomeric red fluorescent protein) under 
the GPR109A promoter. 
 In the second part of this work, we have focused to find receptor for gene by using 
fluorescent microscopy. First step was isolation of blood cells per eye, the retro-orbital 
bleeding method and various modification of cells (without peritonitis, with peritonitis past 
incubation with 4% thioglycolate 2-5 days, protection before coagulation by using EDTA, 
erythrocyte lysis). We made drop with cells on microscope slide and made cell smear 
and stained with Diff-Quick. It was hard to identify expression in blood cells, we have seen 
more erythrocytes than other cells, which can express the receptor GPR109A. Therefore we 
focused on isolation of blood and subsequently peritoneal neutrophils. In the forward step we 
removed peritoneal cells by using peritoneal lavage method. Peritoneal exudates cells 
expressed receptor GPR109A which is to see in fluorescence microscopy.  
 Expression of a functional GPR109A receptor was assessed to specifically induce 
increases in calcium concentrations. We were interested on the effect of nicotinic acid 
and chemokines. The cells were incubated over night with 20 nM GM-CSF to differentiation 
immature monocytes into macrophages, GM-CSF was washed in the morning. Addition 
of nicotinic acid to fura-2 loaded peritoneal exudates cells led to transient changes. Peak 
calcium levels were observed. All cells didn’t express detectable levels of GPR109A surface 
protein, didn’t responded with increases in calcium ions. In contrast, addition of FMLP 
demonstrated that the cells were properly loaded and responsive, in principle. These data 
suggested that if positive control worked then the cells didn’t have functional receptors 
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of chemokines. This may be due for example long time of incubation overnight. Therefore we 
tested also with cell lines THP-1.  
  It is necessary to repeat more experiments with various conditions; it depends 
on duration of inflammation caused by injection 4% thioglycolate, on duration incubation, 
on concentrations added agonists, on time of measurement and lot of other interventions.  
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